Search clinical trials for: CUDC-101

Total 4147 results

Aclaris Therapeutics, Inc.

Completed

Dose-Response Profile of A-101 in Subjects With Seborrheic Keratosis

Seborrheic Keratosis

United States
Marijn Lijffijt, PhD
Michael E. DeBakey VA Medical Center; VistaGen Therapeutics, Inc.

Completed

Electrophysiological Biomarkers of AV-101

Healthy

United States
Eleusis Therapeutics
Beckley Psytech Pty Ltd

Recruiting

ELE-101 Safety & Tolerability Study in Healthy Participants and Patients With Depression

Depression | Healthy Volunteers | Major Depressive Disorder

United Kingdom
Bioray Laboratories
Institute of Hematology & Hospital of Blood Diseases, Chinese Academy of...

Not yet recruiting

Clinical Study on the Safety and Efficacy of BRL-101 in the Treatment of Sickle Cell Disease

Sickle Cell Disease
Mineralys Therapeutics Inc.

Completed

Trial on the Safety and Efficacy of MLS-101 in Patients With Uncontrolled Hypertension (Target-HTN)

Hypertension, Renal

United States
Ascenta Therapeutics

Completed

Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPC

Prostate Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors

Locally Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
UCB Biopharma SRL

Completed

A Study to Assess the Pulmonary Safety of Staccato Alprazolam in Healthy Study Participants and in Study Participants With Mild Asthma

Healthy Study Participants | Participants With Mild Asthma

United States
Auspex Pharmaceuticals, Inc.

Completed

A Pilot Study Of SD-809 (Deutetrabenazine) In Moderate To Severe Tourette Syndrome (TS)

TOURETTE SYNDROME

United States
Impax Laboratories, LLC

Completed

Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease

Idiopathic Parkinson's Disease

United States
Corbus Pharmaceuticals Inc.
Cystic Fibrosis Foundation

Completed

Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis

Cystic Fibrosis

United States, United Kingdom, Sweden, Canada, France, Austria, Germany, Netherlands, Italy, Belgium, Portugal, Bulgaria, Czechia, Greece, Hungary, Poland, Romania, Russian Federation, Serbia, Slovakia, Spain
Aurigene Discovery Technologies Limited

Completed

A Phase II Study to Evaluate Efficacy & Safety of AUR101 in Patients of Moderate-to-Severe Psoriasis (INDUS-2)

Chronic Plaque-type Psoriasis

India
Emerald Health Pharmaceuticals

Completed

To Evaluate the Safety and Tolerability, Pharmacokinetics, Food-effect and Pharmacodynamics of EHP-101 in Healthy Volunteers

Healthy

Australia
Bioray Laboratories
Xiangya Hospital of Central South University; First Affiliated Hospital of... and other collaborators

Enrolling by invitation

Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-Thalassemia

Beta-Thalassemia

China
Corbus Pharmaceuticals Inc.
University of Pennsylvania; National Institute of Arthritis and Musculoskeletal...

Terminated

Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis

Dermatomyositis

United States
Scioderm, Inc.
Amicus Therapeutics

Completed

ESSENCE Study: Efficacy and Safety of SD-101 Cream in Participants With Epidermolysis Bullosa

Epidermolysis Bullosa

Italy, Spain, Serbia, United States, Australia, Netherlands, Austria, Germany, Israel, Lithuania, France, United Kingdom, Poland
AL-S Pharma

Recruiting

A Study to Evaluate, Safety, Tolerability, Pharmacodynamic (PD) Markers and Pharmacokinetics (PK) of AP-101 in Participants With Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

Korea, Republic of, United States, Canada, Germany, Sweden, Belgium
QurAlis Corporation

Completed

A Study Evaluating Safety, Tolerability, and Pharmacokinetics of QRL-101 in Healthy Participants

Healthy Volunteers

Netherlands
Veloxis Pharmaceuticals

Completed

A Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VEL-101

Healthy Volunteers

United States
Inversago Pharma Inc.

Completed

Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of INV-101 in Healthy Male and Female Subjects

Pharmacokinetic

Canada
Acanthas Pharma Inc

Withdrawn

A Study of Single Ascending Doses of STAR-101 in Healthy Participants

Healthy Volunteers
Arava Bio Tech Ltd.

Unknown

Safety and Efficacy of Topical AR/101 Compared With Placebo, in Accelerating Granulation Tissue Formation of Hard-to-heal Wounds

Wounds | Other Ulcers Wounds and Skin Problems

Israel
Minerva Neurosciences

Completed

Pharmacokinetic Study of MIN-101 in Healthy Subjects

Schizophrenia

United Kingdom
Alaunos Therapeutics

Unknown

A Phase II Trial of ZIO-101 in Advanced Multiple Myeloma: Protocol SGL2001b

Multiple Myeloma

United States
Alaunos Therapeutics

Unknown

A Phase-II Trial of ZIO 101 in Advanced Hepatocellular Carcinoma

HEPATOCELLULAR CARCINOMA

United States
Tianjin ConjuStar Biologics Co., Ltd.

Recruiting

Study SC-101 in Subjects With Advanced Malignancies

Advanced Solid Tumor

China
Ankyra Therapeutics, Inc

Recruiting

Phase I Study of ANK-101 in Advanced Solid Tumors (ANCHOR)

Solid Tumor | Non Small Cell Lung Cancer | Advanced Solid Tumor | Metastatic Solid Tumor | Malignant Solid Tumor | Cutaneous Tumor | Subcutaneous Tumor | Metastasis to Soft Tissue

United States, Canada
Betta Pharmaceuticals Co., Ltd.

Recruiting

BPB-101 in Subjects With Metastatic or Locally Advanced Solid Tumors

Solid Tumor

China
Aardvark Therapeutics, Inc.
Children's Hospital Colorado; Stanford University

Recruiting

A Study of Oral ARD-101 in Patients With Prader-Willi Syndrome

Prader-Willi Syndrome

United States
CorrectSequence Therapeutics Co., Ltd
First Affiliated Hospital of Guangxi Medical University

Active, not recruiting

A Clinical Study Evaluating the Safety and Efficacy of CS-101 in Treating Subjects With β-thalassemia

Beta-Thalassemia

China
Blue Blood Biotech Corp.

Completed

BB-101 for Treatment of Diabetic Lower Leg and Foot Ulcers

Diabetic Foot Ulcer

Taiwan
Paean Biotechnology Inc.

Completed

Allogeneic Mitochondria (PN-101) Transplantation for Refractory Polymyositis or Dermatomyositis

Dermatomyositis | Polymyositis

Korea, Republic of
Fervent Pharmaceuticals
ICON plc

Completed

FP-101 Versus Placebo in the Treatment of Menopausal Vasomotor Symptoms

Vasomotor Symptoms | Menopause

United States
Asklepios Biopharmaceutical, Inc.

Active, not recruiting

AAV2/8-LSPhGAA (ACTUS-101) in Late-Onset Pompe Disease

Pompe Disease

United States
Dr. Anupam Sehgal
Taysha Gene Therapies, Inc.; GlycoNet

Active, not recruiting

First-in-Human Study of TSHA-101 Gene Therapy for Treatment of Infantile Onset GM2 Gangliosidosis

Infantile GM2 Gangliosidosis (Disorder)

Canada
Innovo Therapeutics, Inc.

Completed

First in Human, Single Ascending Dose Study

Ulcerative Colitis

Korea, Republic of
Invenux, LLC
State University of New York - Downstate Medical Center

Active, not recruiting

Dose-Escalation Study of SCD-101 in Sickle Cell Disease

Sickle Cell Disease | Sickle-Beta Zero Thalassemia

United States
Flame Biosciences

Withdrawn

FL- 101 Study in Non-Metastatic MIBC

Muscle Invasive Bladder Carcinoma
Abeona Therapeutics, Inc

Terminated

A Long-term Follow-up Study of Patients With MPS IIIB Treated With ABO-101

Mucopolysaccharidosis III-B

United States, Germany, France
AL-S Pharma

Unknown

A Study to Evaluate AP-101 in Familial and Sporadic Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

Canada
United BioSource, LLC
AveXis, Inc.

Approved for marketing

AveXis Managed Access Program Cohort for Access to AVXS-101

Spinal Muscular Atrophy

United States
Minerva Neurosciences

Completed

A Pharmacokinetic Study of Modified Release (MR) Formulations of MIN-101 in Healthy Subjects

Healthy Subjects

Ireland
Healthpoint

Completed

Cumulative Irritation Potential of 828 Ointment

Healthy Volunteers

United States
Healthpoint

Terminated

Evaluation of Effects of HP828-101 for Moisture Associated Skin Damage

Skin Abnormalities

United States
Norgine

Completed

A Study in Healthy Male Subjects Designed to Assess the Mass Balance Recovery and Pharmacokinetics of 14C TZP-101

Postoperative Ileus

United Kingdom
M.D. Anderson Cancer Center
Alaunos Therapeutics

Completed

Phase I Trial of ZIO-101 in Patients With Solid Tumors

Solid Tumors

United States
Carmot Australia First Pty Ltd
Carmot Therapeutics, Inc.

Recruiting

Phase 1 Study of CT-996 in Overweight/Obese Participants and Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes | Overweight or Obesity

Australia
Carmot Therapeutics, Inc.

Recruiting

A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants With Type 1 Diabetes

Type 1 Diabetes

United States
Carmot Therapeutics, Inc.

Completed

A Study to Assess CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood Glucose.

Diabetes

United States
KU Leuven

Completed

The Impact of Real-time Feedback on Physical Activity Patterns in Flemish Employees

Sedentary Lifestyle

Belgium

Search clinical trials for: CUDC-101

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Moldova

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations